webinar register page

Webinar banner
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma

01:23:00

Apr 16, 2021 11:45 AM

Webinar logo
* Required information
Loading

By registering, I agree to the Privacy Statement and Terms of Service.

Register

Speakers

Rafael Fonseca, MD
Interim Director, Mayo Clinic Arizona @Mayo Clinic Cancer Center, Phoenix AZ
Rafael Fonseca, M.D., is the interim director of Mayo Clinic Cancer Center and is the director for Innovation and Transformational Relationships at Mayo Clinic's campus in Arizona. Dr. Fonseca has a broad range of research interests, including clinical trials for the treatment of myeloma and related conditions, a better understanding of the genetics of myeloma and related conditions (including the clinical implications), new drug development (including harnessing the cells' metabolism to develop effective therapies), myeloma bone disease, pharmacoeconomics, and policy. His research laboratory is currently composed of five full-time technologists and three postdoctoral fellows.
Jack Aiello
Patient Advocate & Myeloma Survivor, San Jose, CA @Patient Advocate
Jack Aiello is a multiple myeloma survivor and is an active volunteer with LLS, MMRF, and IMF among others. Jack is involved with cancer advocacy organizations such as the International Myeloma Foundation, Multiple Myeloma Research Foundation, The Leukemia & Lymphoma Society (LLS) and Myeloma Crowd, all of which provide research dollars and education programs for multiple myeloma. He also serves (served) on myeloma committees which focus on developing clinical trials, offering his patient perspective to the National Cancer Institute, SWOG Cancer Research Institute, BMT Clinical Trials Network, and Stanford’s Scientific Review Committee.
James Berenson, MD
Founder, President and Medical and Scientific Director of the IMBCR @Berenson Cancer Center and IMBCR
Dr. Berenson has his private practice in West Hollywood, California and has specialized in the treatment of patients with multiple myeloma, MGUS, amyloidosis, Waldenstrom’s macroglobulinemia and metastatic bone disease as well as conducting research related to these disease both in the basic and clinical areas for more than 20 years. He has been involved in many of the major breakthroughs that have brought new treatments for patients with these diseases resulting in both an improvement in the length and quality of their lives.